secwatch.observer — SEC 8-K summary
======================================

Issuer:     HERON THERAPEUTICS, INC. /DE/ (HRTX)
CIK:        0000818033
Form:       8-K
Filed at:   2025-10-29T23:59:59+00:00
Accession:  0001193125-25-256300
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Heron Therapeutics appoints Thomas Cusack to board under Rubric Capital agreement
--------------------------------------------------------------------------------

- Thomas Cusack appointed to Heron's board effective Oct 27, 2025; term expires at 2026 annual meeting.
- Cusack was Managing Director at Starboard Value LP (approx. $9B AUM) from 2011-2025.
- Appointment made pursuant to Cooperation Agreement with Rubric Capital Management LP dated Aug 8, 2025.
- Cusack will serve on the Nominating and Corporate Governance Committee.
- Director compensation follows standard non-employee director program described in April 2025 proxy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/818033/000119312525256300/0001193125-25-256300-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/818033/000119312525256300/hrtx-20251027.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-256300

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer